HK1116778A1 - - Google Patents

Info

Publication number
HK1116778A1
HK1116778A1 HK08107504.6A HK08107504A HK1116778A1 HK 1116778 A1 HK1116778 A1 HK 1116778A1 HK 08107504 A HK08107504 A HK 08107504A HK 1116778 A1 HK1116778 A1 HK 1116778A1
Authority
HK
Hong Kong
Application number
HK08107504.6A
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1116778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1116778A1 publication Critical patent/HK1116778A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08107504.6A 2005-07-20 2008-07-08 HK1116778A1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12
PCT/US2006/027878 WO2007015871A1 (en) 2005-07-20 2006-07-18 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
HK1116778A1 true HK1116778A1 (xx) 2009-01-02

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107504.6A HK1116778A1 (xx) 2005-07-20 2008-07-08

Country Status (34)

Country Link
US (4) US8163904B2 (xx)
EP (2) EP2186808B1 (xx)
JP (1) JP5129132B2 (xx)
KR (3) KR101755137B1 (xx)
CN (1) CN102267981A (xx)
AR (1) AR057467A1 (xx)
AT (1) ATE514689T1 (xx)
AU (2) AU2006276205B2 (xx)
BR (1) BRPI0613605A2 (xx)
CA (2) CA2823946C (xx)
CY (1) CY1111772T1 (xx)
DK (1) DK1910336T3 (xx)
EC (1) ECSP088118A (xx)
ES (1) ES2634291T3 (xx)
GT (1) GT200600316A (xx)
HK (1) HK1116778A1 (xx)
HR (1) HRP20110639T1 (xx)
IL (1) IL187787A (xx)
JO (1) JO2757B1 (xx)
MA (1) MA29686B1 (xx)
MX (1) MX2008000892A (xx)
MY (1) MY149889A (xx)
NO (1) NO341313B1 (xx)
NZ (2) NZ591142A (xx)
PE (1) PE20070241A1 (xx)
PL (1) PL1910336T3 (xx)
PT (1) PT1910336E (xx)
RU (4) RU2509767C1 (xx)
SG (1) SG170772A1 (xx)
SI (1) SI1910336T1 (xx)
TN (1) TNSN08028A1 (xx)
TW (1) TWI455934B (xx)
UY (1) UY29683A1 (xx)
WO (1) WO2007015871A1 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
US20100152198A1 (en) * 2006-04-07 2010-06-17 Manley Paul W Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
JP5486012B2 (ja) 2008-11-05 2014-05-07 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブＨＣｌ結晶形
EP2186514B1 (en) * 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
CA2753637A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
EP2490690A1 (en) 2009-10-23 2012-08-29 Novartis AG Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (xx) 2010-01-15 2016-09-02
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) * 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (en) * 2010-11-26 2014-04-30 Hetero Research Foundation NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
KR20140096035A (ko) 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP6275645B2 (ja) 2011-11-14 2018-02-07 ノバルティス アーゲー ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
WO2014059518A1 (en) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Solid forms of nilotinib hydrochloride
MX2015004947A (es) * 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
JP2016522182A (ja) * 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
LT3189045T (lt) * 2014-08-11 2022-04-11 Sun Pharmaceutical Industries Limited Naujos nilotinibo druskos ir jų polimorfai
US10301282B2 (en) 2015-03-20 2019-05-28 Cipla Limited Polymorphic form X of nilotinib dihydrochloride hydrate
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
PL3430004T3 (pl) 2016-03-14 2021-01-25 Pliva Hrvatska D.O.O. Postaci soli nilotynibu w stanie stałym
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20230075170A1 (en) 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE60034963D1 (de) * 1999-12-14 2007-07-05 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
ECSP088118A (es) 2008-02-20
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
NZ564182A (en) 2011-03-31
RU2013101749A (ru) 2014-07-27
TW200800950A (en) 2008-01-01
CA2615669A1 (en) 2007-02-08
CY1111772T1 (el) 2015-10-07
ES2634291T3 (es) 2017-09-27
BRPI0613605A2 (pt) 2011-01-18
IL187787A0 (en) 2008-08-07
ATE514689T1 (de) 2011-07-15
RU2011120363A (ru) 2012-11-27
TNSN08028A1 (en) 2009-07-14
CA2615669C (en) 2013-11-12
PL1910336T3 (pl) 2011-11-30
AU2006276205A1 (en) 2007-02-08
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
AU2010241419C1 (en) 2024-05-23
RU2483065C2 (ru) 2013-05-27
RU2008105827A (ru) 2009-08-27
KR20150100946A (ko) 2015-09-02
KR20140047737A (ko) 2014-04-22
RU2509767C1 (ru) 2014-03-20
EP2186808A1 (en) 2010-05-19
MY149889A (en) 2013-10-31
HRP20110639T1 (hr) 2011-10-31
CA2823946C (en) 2015-12-29
NO20080897L (no) 2008-02-20
DK1910336T3 (da) 2011-10-03
AU2010241419B2 (en) 2012-03-29
GT200600316A (es) 2007-04-02
US20080200487A1 (en) 2008-08-21
KR20080027855A (ko) 2008-03-28
JP5129132B2 (ja) 2013-01-23
US8163904B2 (en) 2012-04-24
US9163005B2 (en) 2015-10-20
AU2010241419A1 (en) 2010-12-02
EP1910336A1 (en) 2008-04-16
SG170772A1 (en) 2011-05-30
US8389537B2 (en) 2013-03-05
US20130137712A1 (en) 2013-05-30
TWI455934B (zh) 2014-10-11
KR101755137B1 (ko) 2017-07-06
PE20070241A1 (es) 2007-03-22
IL187787A (en) 2012-07-31
MX2008000892A (es) 2008-03-18
NZ591142A (en) 2012-09-28
WO2007015871A1 (en) 2007-02-08
AU2006276205B2 (en) 2010-08-19
US20140038994A1 (en) 2014-02-06
CA2823946A1 (en) 2007-02-08
UY29683A1 (es) 2007-02-28
EP1910336B1 (en) 2011-06-29
JO2757B1 (en) 2014-03-15
CN102267981A (zh) 2011-12-07
EP2186808B1 (en) 2017-04-19
US20120270891A1 (en) 2012-10-25
US8580806B2 (en) 2013-11-12
SI1910336T1 (sl) 2011-10-28
AR057467A1 (es) 2007-12-05
MA29686B1 (fr) 2008-08-01
JP2009502796A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
ECSDI055937S (xx)
BRPI0609157A8 (xx)
BRPI0608519A2 (xx)
IN2006KO00975A (xx)
JP2007027290A5 (xx)
JP2005226832A5 (xx)
JP2005312932A5 (xx)
BRPI0618215B8 (xx)
JP2006201212A5 (xx)
BY2237U (xx)
CN105122969C (xx)
CN300726592S (zh) 碗用具（双壁式4）
CN300726008S (zh) 鞋帮
CN300725994S (zh) 鞋底
CN300726698S (zh) 调料瓶套装(e)
CN300726004S (zh) 鞋帮
CN300725995S (zh) 鞋帮
CN300852031S (zh) 瓶
CN300725993S (zh) 鞋帮
CN300725996S (zh) 鞋帮
CN300726697S (zh) 调料瓶套装(b)
CN300726696S (zh) 调料瓶套装(c)
CN300726695S (zh) 调料瓶套装(a)
CN300726699S (zh) 调料瓶套装(d)
CN300726591S (zh) 冷冰食品制作器